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Antibody to a cryptic solid phase Clq antigen in membranoproliferative
nephritis. IgG containing material detected in membranoproliferative
nephritis (MPGN) serum with a solid phase (sp) Clq ELISA has been
presumed to be immune complexes. However, in serum from 13 MPGN
patients containing large amounts of spClq-binding material, sucrose
density ultracentrifugation and sieve chromatography showed spClq-
binding protein to sediment at 7S or cofractionate with IgG. One serum
(stored for 12 years) contained, in addition, spClq-binding material
sedimenting at more than 19S. Isolated MPGN IgG was shown to bind
to spClq. SpClq-binding material could be totally removed from MPGN
serum by absorption with BSA-anti-BSA immune precipitates, and by
acid elution of the precipitates IgG binding to spClq could be recovered.
F(ab')2, isolated from pepsin digested MPGN IgG, continued to bind
spClq. Binding of MPGN IgG or F(ab')2 to spClq was not inhibited by
2MNaCl. Incubation of MPGN serum with 1251 Clq followed by sucrose
density ultracentrifugation resulted in a peak of radioactivity at I 1S, the
sedimentation rate of Clq, giving evidence that material binding fluid
phase Clq is not present. SpClq-binding IgG was detected in 54% of 68
MPGN patients. These results indicate that the 7S spClq-binding IgG
represents antibody to a cryptic antigen revealed only when Clq fixes to
a solid surface.
Circulating immune complexes have been identified in a high
proportion of patients with systemic lupus erythematosus
(SLE) and membranoproliferative glomerulonephritis (MPGN).
A well recognized, antigen non-specific assay for circulating
complexes utilizes their ability to bind by the Fe portion of IgG
to solid phase (sp) Clq. The immune complexes are detected
and quantitated by the binding of labeled antibody to their
constituent IgG. However, by ultracentrifugation or gel filtra-
tion of SLE serum, the spClq-binding material was often found
to sediment at 7S or cofractionate with IgG [1—9]. In a recent
study, Uwatoko et al [71 found that in all of 15 SLE sera the
predominant material binding to spClq was of low molecular
weight and cofractionated with monomeric IgG. The present
study reports the characteristics of the spClq-binding material
in MPGN sera and conclusively demonstrates that it is not
immune complexes but is composed of antibody to a cryptic
antigen revealed on Clq when it is fixed to a solid phase.
Methods
Patient and control serum
Serum specimens, obtained from 68 patients with MPGN and
from 36 healthy volunteers (NHS), were used fresh or after
storage at —70°C. The diagnosis of MPGN and classification as
to Type I, II or III was made by electron microscopy of renal
biopsy specimens according to previously published criteria
[101.
Iso,'ation of IgG and F(ab')2 fragments
IgG was partially purified from whole serum by 33%
(NH4)2S04 precipitation [11], dissolved in one-half the original
serum volume of 0.01 M phosphate buffer, pH 7.4 (PB), con-
taining 0.15 M NaCI (PBS) and dialyzed for 48 hours against
PBS. IgG was further purified by anion exchange chromatogra-
phy using a 5 x 29 cm DEAE Sephacryl (Pharmacia, Inc.,
Piscataway, New Jersey, USA) column after equilibration with
PB [11]. F(ab')2 was cleaved from IgG by pepsin digestion in 0.1
M sodium acetate containing 0.15 M NaCI, pH 4.0 for 18 hours
at 37°C. The digest was neutralized by dialysis against PBS, pH
7.5 and the F(ab')2 fragment isolated by chromatography on
Sephadex G-150 superfine (Pharmacia) equilibrated with PBS.
Antibodies
Peroxidase-conjugated goat antibody to human IgG and af-
finity purified antibody to human F(ab')2 were purchased from
Cappell Laboratories (Cochranville, Pennsylvania, USA). Per-
oxidase-conjugated rabbit antibody to goat IgG was purchased
from Calbiochem/Behring Diagnostics (San Diego, California,
USA). Goat antibody to bovine serum albumin (BSA) and to
human Clq were prepared in this laboratory [12, 13]. Immuno-
fluorescence of kidney biopsies with labeled antibody to human
Clq and IgG [13, 14] was graded on a scale of 0 to 4.
Protein concentrations and purity
Total protein concentrations were measured by the method of
Lowry et al [15] or estimated from the optical density (OD) at
280 nm. Albumin, Clq, IgG and 1gM were measured by radial
immunodiffusion (RID) using monospecific anti-sera prepared
in this laboratory. Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE), performed as described by
Laemmli [161 using an 8% running gel and 4% stacking gel for
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3.5 hours at 15 mA, was used to evaluate the purity of protein
preparations.
Clq
Clq was isolated as described by Tenner, Lesavre and
Cooper [17] or purchased from Calbiochem/Behring Diagnos-
tics, aliquoted and stored at —70°C. Clq was radiolabeled with
1125 (Amersham, Arlington Heights, Illinois, USA) using lodo-
beads (Pierce Chemical Co., Rockford, Illinois, USA) [181 to a
specific activity of 0.2 j.tCi/tg Clq.
Solidphase Clq enzyme-linked immunosorbent assay (spClq
ELISA)
The spClq ELISA is similar to the Clq-microplate ELISA
described by Singh and Tingle [19]. In the spClq ELISA, Clq (5
tg/ml in 0.05 M carbonate buffer, pH 9.6) coated polystyrene
microtiter plates (Flow Laboratories, Inc., McLean, Virginia,
USA), were blocked with 0.2% BSA in carbonate buffer. After
washing with PBS containing 0.04 M disodium ethylene-diamine
tetra acetic acid (EDTA) and 0.05% Tween 20 (TW), serum,
serum fractions or aggregated human gammaglobulin (AHG)
standards diluted 1:20 in PBS-EDTA-TW were added to wells
in triplicate. Standards were prepared from AHG [20] stock
serially diluted in pooled NHS maintained at 4°C. The plates
were incubated at 37°C for two hours and washed with PBS-
TW. Peroxidase-conjugated anti-human IgG (1:1000) or anti-
human F(ab')2 (1:100) diluted in PBS-TW was added and the
plates incubated for one hour at 37°C. Peroxidase activity,
detected by o-phenylenediamine (Sigma Chemical Co., St.
Louis, Missouri, USA) [21], was measured at 492 nm in a
Titertek Multiskan (Flow Laboratories). The standard curve
was constructed on semilog paper and the results expressed as
equivalents of AHG in tg/ml. In some experiments the concen-
tration of NaCl in the PBS-EDTA-TW was increased.
Ultracentrfugation and gel filtration of NHS and MPGN
serum
Samples were diluted 1:2 in PBS and 0.15 ml layered on 4.8
ml 10 to 30% linear sucrose gradients made in PBS. The
gradient tubes were centrifuged at 35,000 rpm for 17 hours in a
Beckman LS-70M ultracentrifuge (Beckman Instruments, Inc.,
Palo Alto, California, USA) using a SW5O. 1 rotor. Fractions of
10 to 15 drops were collected by puncturing the bottom of the
tube. Where indicated, gel filtration of sera was carried out on
Sephacryl S-300 (Pharmacia, Inc.) equilibrated with PBS. Total
protein, albumin, IgG, 1gM and spClq ELISA were determined
in each fraction where appropriate.
Immune complexes
BSA-anti-BSA immune precipitates, used to absorb spClq
binding material from serum, were prepared as described pre-
viously [12]. Tetanus toxoid (Squibb Laboratories, Inc., Mar-
ietta, Pennsylvania, USA) and human anti-tetanus globulin
(Cutter Biological, Berkeley, California, USA) were mixed at
equivalence, incubated at 37°C for one hour and then overnight
at 4°C. The complexes were centrifuged at 13,500 RPM for five
minutes and the precipitate washed twice with PBS. The final
precipitate was resuspended in PBS and used, after dilution in
PBS-EDTA-TW containing variable concentrations of NaC1, to
test the affect of the concentration of NaCI on Fc binding to
spClq.
Results
Fractionation ofspClq-binding material in MPGN sera by
ultracentrifugation and gel filtration
The sedimentation coefficients of spClq-binding material in
serum specimens from 13 patients with MPGN (8 with Type I,
1 with Type II and 4 with Type III) were determined by sucrose
density ultracentrifugation. In all 13 sera, spClq-binding mate-
rial was detected between 6S and 8S (Fig. 1). Only one MPGN
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Fig. 1. Sucrose density ultracentr,fugation of
serum from a patient with MPGN Type III
and NHS. The total protein (. . .) is graphed
as the O.D. at 700 nm after reaction with
Folin reagent [15]. SpClq-binding IgG was
measured in each fraction of NHS (G—C)
and patient serum ( •) by ELISA and is
graphed as the O.D. at 492 nm. Fractions
containing maximum concentrations of 1gM
(l9S), lgG (7S) and albumin (4S) are
indicated.
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serum specimen, which had been stored at —70°C for 12 years,
contained rapidly sedimenting, high molecular weight, spClq-
binding material in addition to material binding spClq at 7S.
Wener and Mannik [221 have shown that fixation of large
immune complexes to the surface of the ultracentrifuge tubes
during sucrose density gradient ultracentrifugation can be pre-
vented by incorporating TW into the sucrose solution and
precoating the tubes with gelatin. No rapidly sedimenting (>8S)
spClq-binding material was detectable in the other 12 specimens
when ultracentrifuged using this modification.
The possibility that the 6S to 8S spClq-binding material in
MPGN sera represented aggregates of IgG fragments produced
by the sucrose or IgG dissociated from immune complexes by
sucrose was investigated. Serum from four MPGN patients with
6S to 8S spClq-binding material exceeding 100 g AHG Eq/mi
were fractionated by column chromatography on Sephacryl
S-300. In each instance, spClq-binding material cofractionated
with monomeric IgO. In addition, monomeric IgG isolated from
four MPGN sera containing large amounts of spClq-binding IgG
bound to spClq while IgG isolated from NHS did not.
Elution of spClq-binding IgG from an immune precipitate
IgG in MPGN serum which bound to Clq deposited on
polystyrene bound equally well to Clq deposited on an immune
precipitate. As shown in Table 1, when chelated MPGN serum
containing a large amount of spClq-binding IgG was incubated
with a BSA-anti-BSA immune precipitate, almost all spClq-
binding IgG was absorbed to the precipitate. After extensive
washing with PBS, the precipitate was eluted with glycine
buffer, pH 2.5, the eluate pH was returned to 7.4 with 0.15 M
TRIS-HC1 buffer, pH 8.2 and its volume reconstituted to that of
the original serum. By spClq ELISA, the eluate contained
spClq-binding material in a concentration of greater than 500 g
AHG Eq/ml and immunochemically IgG was found to be
present. In contrast, when MPGN serum was preheated to 56°C
for 30 minutes to destroy Clq prior to incubation with the
MPGN I MPGN 111
Initial All Initial All
biopsy biopsies biopsy biopsies
Number of biopsies 12 28 12 19
Number (%) 10 (83%) 20 (71%) 5 (4l%)a 9 (47%)
biopsies with
immunofluorescence
with anti-IgG
Number (%) 7 (58%) 15 (54%) 3 (25%) 4 (21%)
biopsies with
immunofluorescence
with anti-Clq
Number (%) with serum 7 (58%) 19 (68%) 6 (50%) 11(58%)
anti-spClq >10 g
AHG Eq/ml
Number (%) with serum 5 (42%) 11(39%) 2 (17%) 5 (26%)
anti-spClq >10 g
AHG Eq/mi and
immunofluorescence
with anti-lgG
Number (%) with serum 4 (3 3%) 10 (36%) 1 (8%) 2 (11%)
anti-spClq >10 sg
AHG Eq/ml and
immunofluorescence
with anti-Clq
immune precipitate, the spClq-binding IgG remained in the
serum and virtually none could be eluted from the immune
precipitate.
Effect of NaCI concentration on the binding of AHG, immune
complexes and MPGN spClq-binding IgG to spClq
The effect of various NaC1 concentrations on spClq-binding
of AHG, tetanus-human anti-tetanus immune complexes, goat
anti-human Clq and the spClq-binding IgG in MPGN serum was
tested by addition of NaC1 to PBS-EDTA-TW used to dilute the
sample in the microtiter plate well. As shown in Figure 2, with
increasing NaC1 concentration, binding of AHG or tetanus-
human anti-tetanus immune complexes to spClq was inhibited,
while binding of goat anti-human Clq or IgG in sera from
patients with MPGN to spClq was unchanged, The results
provide strong evidence that the IgG in MPGN serum is binding
to spClq by an antigen combining site rather than by the Fc.
Binding of F(ab')2 from normal and MPGN IgG to spClq
As further evidence that spClq binding of MPGN IgG is via
its F(ab')2 rather than Fc, the binding of NHS and MPGN sera,
the IgG isolated from them and their F(ab')2 fragments are
compared in Figure 3. All measurements were made using 2M
NaC1 to rule out binding by the Fc. The results are the averages
of two experiments. MPGN sera and the IgG and F(ab')2
fragments isolated from these sera bound well to spClq as
compared to the slight binding of IgG and F(ab')2 from normal
sera. The consistently low binding of the IgG and F(ab')2 as
compared to the serum from patient H 1011 with MPGN I is
Table 1. Absorption of spClq-binding IgG in MPGN serum to BSA-
anti-BSA immune precipitates
Solid
phase Clq
ELISA
tg AHG
Reaction mixture Eq/mi
Table 2. Correlation of circulating antibody to spClq with glomerular
IgG and Clq deposition in patients with Types I and III MPGN who
had measurements of circulating antibody to spClq at the time of
their renal biopsy
supernatant 4
EDTA 4°C /
BSA-anti-BSA + MPGN serum
Immune ppt 12 hr
acid
precipitate — >500
eluate
supernatant >500
EDTA 4°C
BSA-anti-BSA + MPGN serum
Immune ppt 56°C x 30 mm 12 hr acid
precipitate — <2
eluate
MPGN serum contained> 500 ig AHG Eq/mi
a Immunofluorescence with anti-IgG in MPGN III was considerably
less intense than in MPGN I. In MPGN III IgG immunofluorescence
was graded a mean (± SD) of 0.54 0.81, whereas in MPGN I the mean
grade was 1.41 1.12.
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Fig. 2. The effect of increasing NaCI concentration on spClq binding,
measured by spClq ELISA and expressed as O.D. at 492 nm, of 3
different MPGN sera (•); AHG, 250 xg/ml (X); tetanus-human anti-
tetanus immune complexes (0); andgoat anti-Clq diluted 1:250 (s).
unexplained. This serum sample had been stored for a long
period and was the only one which contained high sedimenting
spClq binding material by sucrose density gradient analysis.
Evidence against binding of fluid phase Clq to MPGN spClq-
binding IgG
I25J Ciq, 100 ng, was incubated for 60 minutes at 26°C and for
60 minutes at 4°C with 0.1 ml of MPGN serum containing high
levels of spClq-binding IgG and with NHS. 1251 Clq was also
incubated with NHS and patient sera which had been heated to
56°C for 30 minutes, chelated with 0.2 M EDTA or both chelated
and heated. After incubation, the mixtures were centrifuged on
10 to 30% sucrose density gradients containing 0.04 M EDTA.
Total protein, albumin, IgG, 1gM and radioactivity were mea-
sured in each fraction (Fig. 4). In no mixture did the 1251
sediment faster than I iS, indicating that fluid phase Clq did not
bind to anti-spClq or any other serum component.
Presence of spClq-binding IgG (anti-spClq) in normal and
MPGN sera
IgG binding to spClq (anti-spClq) was quantitated by spClq
ELISA in serum from 36 adult volunteers and 68 patients with
MPGN (Fig. 5). The upper limit of normal for the spClq ELISA
was calculated as the mean SD for the results on 35 of the 36
specimens of NHS. The serum specimen omitted from the
calculations was from a 45-year-old healthy male and contained
large amounts of spClq-binding IgG which, upon sucrose den-
sity gradient ultracentrifugation, was 7S. Subsequent serum
specimens from this individual have continued to contain large
amounts of anti-spClq. While screening other normal sera for
use as controls in various experiments, three additional normal
subjects were identified whose serum contained large amounts
of anti-spClq. The sera from a 68-year-old healthy male con-
tained large amounts of spClq-binding IgG which cofractionated
by sucrose density gradient ultracentrifugation with monomeric
IgG. Pepsin digestion of the IgG and isolation of F(ab')2
indicated that the binding to spClq was by its antigen combining
5
Normal MPGN I MPGN I MPGN Ill
H1011 A1013 P0113
Fig. 3. Comparison of the binding to spClq of whole serum (open
columns), isolated !gG (black columns) and F(ab')2 (shaded columns)
from patients with MPGN and normal subjects. All measurements were
made with the samples in 2 M NaCI. Detection of binding to spClq was
by peroxidase conjugated antibody to F(ab')2 and is expressed in g
AHG Eq/mg IgG or F(ab')2. Note the change in scale of the ordinate at
the broken line.
site. In addition, serum containing antinuclear antibody in a
speckled pattern from two healthy females, aged 24 and 26,
contained elevated levels of anti-spClq. One serum contained,
in addition, extractable nuclear antigen and the other anti-
thyroid antibody.
In serum specimens obtained as close to the time of diagnosis
of MPGN as possible, anti-spClq was elevated in 37 of 68 (54%).
The auto-antibody was found in 19 of 26 (73%) with Type I, 7 of
16 (44%) with Type II and 11 of 26 (42%) with Type III (Fig. 5).
Anti-spClq was measured serially on specimens obtained more
than one month apart from 30 patients. Among 13 patients with
initial levels less than 10 g AHG Eq/mi, the level in two
increased in at least one subsequent measurement to greater
than 10 /Lg/ml, whereas of the 17 patients with initial levels
greater than 10 g/m1, 14 continued to have elevated levels for
as long as 12 years and 3 showed progressive decreases to less
than 10 g AHG Eq/mi.
All patients were considered to have active disease at the
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Fig. 4. Sucrose density gradient (10—30%)
ultracentrfugation of chelated MPGN serum
containing large amounts of spClq-binding
IgG after incubation with fluid phase 125j Clq.
Total protein (. . .) is represented as the O.D.
at 700 nm, spClq ELISA ( I) is depicted
by the O.D. measured at 492 nm, and
radioactivity (CPM) of each fraction (— —) are
shown. S rate was estimated as in Figure 1.
• had evidence for circulating anti-spClq. The course of each
patient was graded as "doing well" or "deteriorating" and
correlated with the presence of antibody to spClq. No correla-
tion existed. Thus, we were unable to correlate the presence of
55 antibody to spClq to disease activity either initially or during
long term follow-up.
• The presence of glomerular IgG and Clq were correlated with
$ the concentration of circulating antibody to spClq at the time ofthe initial renal biopsy and at the time of all renal biopsies for
patients with Types I and III MPGN. Circulating antibody to
• spClq did not correlate significantly with either the presence or
• amount of glomerular deposits of either IgG or Clq in either
Type I or Type III MPGN by both Chi Square and regression
analysis. Similarily, no relation could be found between the
— — — serum concentrations of antibody to spClq and Clq.
•
Discussion
In 1976 Hay, Nineham and Roitt [231 introduced a radioim-
munoassay to measure serum levels of immune complexes.
This assay was dependent on the binding of the Pc portion of
the IgG constituent of an immune complex to Clq immobilized
on the surface of a polystyrene tube. It was hoped that
_________
measurement of circulating immune complexes would greatly
MPGN Ill improve our understanding of the pathogenesis of immune
complex glomenslonephritis. However, this assay as well as
those developed subsequently have given results which corre-
late poorly both with each other and with the activity of the
glomerulonephntis [24].
The lack of association between circulating immune complex
levels and disease activity in MPGN [20] led us to investigate
the characteristics of the material binding to spClq. We were
surprised to find that all 13 MPGN serum samples analyzed
contained spClq-binding IgG that cofractionated with mono-
meric IgG by sucrose density gradient ultracentrifugation. Only
Fig. S. SpC!q-binding IgG concentrations (spClq ELISA) in healthy
adults and in patients with MPGN Types 1, Ii and ill are expressed in
pg AHG Eq/mi. The upper limit of normal is represented by the
horizontal dashed line.
time of their initial renal biopsy. In patients with Types II and
III MPGN no correlation existed between disease activity and
the presence of circulating antibody to spClq since less than half
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one serum sample contained, in addition, high molecular weight
spClq-binding IgG. This sample had been stored frozen for
many years and may have contained aggregates of IgG rather
than high molecular weight immune complexes. In patients with
SLE, investigators using various methods have found small (7S
or less) IgG containing material which bound spClq [1—9] in
addition to moderate (7-19S) [1, 2, 4, 5] and large (> l9S) [1, 3—
5] IgG-containing material. Recently, Uwatoko et al [7] re-
ported that all of fifteen SLE sera contained spClq-binding
material cofractionating with monomeric IgG and Werner et al
[8] found the spClq-binding material to sediment predominantly
in the 6.6S region in 34 of 35 SLE sera.
The low molecular weight spClq-binding protein has been
thought by others [7, 25, 26] to represent: (a) IgG complexed
with an antigen of low molecular weight; (b) IgG which is
autoantibody to Clq; (c) IgG which has been released from an
immune complex; or (d) IgG which has been otherwise altered
to reveal its Fc. Evidence that in MPGN serum this protein is an
IgG autoantibody directed at a cryptic determinant(s) unique to
Clq fixed to a solid phase derives from several observations.
SpClq-binding materjal from four MPGN sera continued to bind
to spClq in the presence of 2 M NaCI as did goat antibody to
Clq. In contrast, complexes known to bind to spClq by the Fc
portion of the IgG such as AHG and tetanus-anti-tetanus
immune complexes, did not bind in the presence of 2 M NaCI.
Others have shown that immune complex binding to spClq is
inhibited by high concentrations of cation [3, 27—29]. In addi-
tion, spClq binding of F(ab')2 obtained by pepsin digestion of
MPGN IgG was approximately equal to that of the original IgG,
whereas there was little binding of the F(ab')2 derived from the
IgG of NHS. Finally, spClq binding material was absorbed by,
and could be eluted from, antigen-antibody precipitates with
acid buffer. The eluted material was IgG and its absorption to
the precipitates depended on the presence of intact Clq.
These results are similar to those of Marder et al [6],
Uwatoko et al [7] and Antes, Heinz and Loos [9] for SLE sera.
Marder et al [6] eluted the protein from SLE serum which
bound to polystyrene beads coated with Clq and found it to be
indistinguishable from normal IgG. Antes et al [91 absorbed
spClq-binding IgG from SLE serum to Clq fixed to cyanogen
bromide activated Sepharose 4B beads. Uwatoko et al [71
observed that maneuvers to destroy the Fc portion of SLE IgG
such as acid treatment, reduction and alkylation or pepsin
digestion had little or no effect on its ability to bind to spClq.
These observations indicate that the spClq-binding material in
both SLE and MPGN serum is an IgG which binds spClq by its
F(ab')2 or antigen receptor. Additionally, in SLE, the spClq-
binding IgG fixes to the collagen-like region of Clq [9, 29, 30]
which is not involved in binding to the Fc portion of IgG [31].
Our observations indicate that MPGN spClq-binding IgG
does not bind to fluid phase Clq. In contrast to the results
reported a number of years ago by Ooi, Vallota and West [32],
we were unable to identify fluid phase binding of Clq to any
serum constituent when 1251 Clq was mixed with chelated and!
or heated MPGN sera known to contain large amounts of
spClq-binding IgG. Marder et al [6], Uwatoko et a! [30, 33] and
Antes et al [9] likewise found that SLE IgG did not bind to fluid
phase Clq or Cl. Golan, Berger and Loos [34] have recently
demonstrated with monoclonal antibodies that the binding of
Clq to immune complexes exposes new antigenic determinants.
These observations lead to the conclusion that the spClq-
binding IgG found in MPGN serum, other nephritic sera and
occasionally in normal serum represents antibody to a cryptic
antigen revealed on the collagen-like region of Clq as a result of
the conformational change which occurs with binding of Clq to
an immune complex [34], and presumably occurs upon Clq
binding to a solid surface.
We investigated serum from a large number of patients with
MPGN to determine the prevalence of this auto-antibody. Of
interest is the observation that autoantibody to spClq was
nearly twice as common in sera from patients with MPGN I
(73%) as compared to sera from patients with MPGN 11(44%)
and MPGN III (42%). We measured autoantibody to spClq in
serial serum samples from 30 MPGN patients and found both
the appearance and the disappearance of autoantibody to be
uncommon. As reported earlier [20], the clinical course of the
patients could not be correlated with serum concentrations of
antibody to spClq.
The presence of anti-spClq in a high percentage of patients
with SLE and MPGN I is unexplained. Perhaps formation of
this autoantibody is initiated by deposition of immune com-
plexes in the glomerular capillaries with fixation of Clq exposing
the neoantigen. Formation of anti-spClq and its reaction with
the deposited Clq would produce additional immune complexes
which could potentiate classical pathway complement activa-
tion. If this autoantibody is involved in glomerulonephritis, its
effect should be greatest in SLE and MPGN I, two diseases in
which IgG and Clq can be identified in glomerular capillaries
[35] and where classical complement pathway activation is
present [35, 36]. However, we were unable to correlate either
the presence or serum concentration of antibody to spClq with
serum Clq depression or the presence or amount of IgG or Clq
on glomerular capillary walls. A role for antibody to spClq in
the pathogenesis of MPGN Types H and III is unlikely since
evidence for classical complement pathway activation is lacking
[35—37] and Clq and IgG are uncommonly identified in the
glomerular capillaries [35, 36, 38].
Autoantibody formation is a prominent feature of SLE.
However, in MPGN only two autoantibodies have been de-
scribed. C3 nephritic factor, an IgG molecule [391 which binds
to and stabilizes the alternative complement pathway conver-
tase [40], C3bBb, thereby fostering continuous activation of C3,
is found in MPGN Type II. Recently, a properdin-dependent
nephritic factor which slowly activates C3, C5 and C9, presum-
ably by stabilizing the C3bBbP complex [41, 42], has been
found in patients with MPGN Types I and III. Like the
autoantibody to spClq, neither of these nephritic factors react
directly with fluid phase C3, B or P but with neoantigens formed
only after these proteins combine. The presence of yet another
autoantibody in MPGN serum suggests that, as in SLE, regu-
lation of antibody production may be dysfunctional.
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